OakChart

Sight Sciences Inc

SGHTHealthcare·Medical Devices·USA·Small·NASD·Nov 11 • 3:59 PM ET

10.92+0.17 (1.58%)
2026-11-11 23:12 CET
Market cap
597.47 USD m
Revenue, TTM
88.39 USD m
Net income, TTM
-28.40 USD m
Free cash flow, TTM
-16.91 USD m
EPS diluted, TTM
-0.52
P/E
-
Compare

Price

SGHT against its 20, 50 and 200-day averages
2050200beat
4.006.008.0010.00627K1.3MVolumeMay 26Jun 26Jul 26Aug 26Sep 26Oct 26Nov 26SGHTclose 10.9220-day 9.3850-day 8.87200-day 6.1410.92

2.2% under the 52-week high of 11.16 on 9 Nov 2026. 52-week low 3.38 on 9 Apr 2026. Last 15 sessions, 30.1% high to low

Volume 0.79× normal · the line is the 50-bar volume average

Profile

SGHT
52-week range, 97% of the way up
3.3811.16

Sight Sciences, Inc. is an ophthalmic medical device company, which focuses on the development and commercialization of surgical and nonsurgical technologies for the treatment of prevalent eye diseases. It operates through the Surgical Glaucoma and Dry Eye segments. The Surgical Glaucoma segment includes OMNI Surgical System for use in minimally invasive glaucoma procedures. The Dry Eye segment offers TearCare System and related components. The company was founded by Paul Badawi and David Y. Badawi in 2011 and is headquartered in Menlo Park, CA.

IndexRUT
Employees186
IPOJul 15, 2021
Beta2.38
ATR, 14d0.57
Rel volume0.79
Short float3.14%
Insider own34.87%
Inst own36.76%

Snapshot

6 groups

Valuation

IndexRUT
Market Cap606.92M
Enterprise Value571.63M
Income-28.40M
Sales88.39M
Book/sh0.89
Cash/sh1.39
Dividend Est.-
Dividend TTM-
Dividend Ex-Date-
Dividend Gr. 3/5Y- -
Payout-
Employees186
IPOJul 15, 2021

Ratios

P/E-
Forward P/E-
PEG-
P/S6.87
P/B12.27
P/C7.84
P/FCF-
EV/EBITDA-
EV/Sales6.47
Quick Ratio4.72
Current Ratio5.04
Debt/Eq0.86
LT Debt/Eq0.73
Option/ShortYes / Yes

Earnings

EPS (ttm)-0.52
EPS next Y-0.45
EPS next Q-0.14
EPS this Y30.27%
EPS next Y12.38%
EPS next 5Y14.04%
EPS past 3/5Y25.78% 0.13%
Sales past 3/5Y2.74% 22.86%
EPS Y/Y TTM41.47%
Sales Y/Y TTM16.23%
EPS Q/Q20.83%
Sales Q/Q25.20%
EarningsNov 04 AMC
EPS/Sales Surpr.2.68% 5.83%

Ownership

Insider Own34.87%
Insider Trans-0.79%
Inst Own36.76%
Inst Trans-6.62%
ROA-25.68%
ROE-50.07%
ROIC-33.50%
Gross Margin87.74%
Oper. Margin-29.52%
Profit Margin-32.13%
SMA2016.36%
SMA5023.18%
SMA20077.91%
Trades-

Technical

Shs Outstand55.22M
Shs Float36.20M
Short Float3.14%
Short Ratio3.58
Short Interest1.14M
52W High11.16 -2.15%
52W Low3.38 223.27%
Volatility9.27% 6.32%
ATR (14)0.57
RSI (14)71.93
Beta2.38
Rel Volume0.79
Avg Volume317.08K
Volume249,741

Performance

Perf Week12.81%
Perf Month30.15%
Perf Quarter31.25%
Perf Half Y122.86%
Perf YTD37.70%
Perf Year55.11%
Perf 3Y522.22%
Perf 5Y-53.53%
Perf 10Y-
Recom1.50
Target Price11.33
Prev Close10.75
Price10.92
Change %1.58%

Analyst ratings

latest 10 of 17
DateActionAnalystRating changeTargetImplied
Oct 15, 2026InitiatedHH.C. WainwrightBuy$14+28.2%
Jul 28, 2026ResumedUUBSBuy$7-35.9%
Jan 05, 2026UpgradePPiper SandlerNeutral → Overweight$9-17.6%
Aug 08, 2025UpgradeLLake StreetHold → Buy$5-54.2%
Dec 06, 2024InitiatedUUBSBuy$5.50-49.6%
Nov 04, 2024DowngradeLLake StreetBuy → Hold$10 → $5-54.2%
Aug 21, 2024InitiatedLLake StreetBuy$10-8.4%
Sep 12, 2023DowngradeWWilliam BlairOutperform → Mkt Perform
Sep 12, 2023DowngradePPiper SandlerOverweight → Neutral$15 → $5.50-49.6%
Sep 12, 2023DowngradeBBofA SecuritiesNeutral → Underperform$10 → $4.50-58.8%

Peers

Mkt cap
TickerCompanyMkt cap
GKOSGlaukos Corp14.63B
ALCAlcon Inc34.93B
RXSTRxSight Inc221.38M
IRIXIRIDEX Corp11.47M
STAAStaar Surgical Co1.34B
BLCOBausch + Lomb Corp7.62B
HROWHarrow Inc1.10B
TARSTarsus Pharmaceuticals Inc3.78B
COOCooper Companies Inc11.97B
OCULOcular Therapeutix Inc1.47B

Insider trading

latest 14 of 100
InsiderRelationshipDateTransactionCostSharesValueTotal heldForm
HAYDEN JEREMY B.Former OfficerNov 05 '26Proposed Sale10.0226,000260,521Nov 05 03:37 PM
Taylor BrentonEVP, Operations & R&DOct 02 '26Sale8.852,98826,453261,990Oct 05 04:43 PM
Bauerlein AlisonChief Operating OfficerOct 02 '26Sale8.8525,260223,627639,449Oct 05 04:43 PM
Rodberg JamesChief Financial OfficerOct 02 '26Sale8.857,20863,812216,829Oct 05 04:42 PM
Badawi DavidChief Technology OfficerOct 01 '26Sale9.057,79770,5551,975,075Oct 05 04:40 PM
Badawi PaulPresident and CEOOct 01 '26Sale9.0529,653268,3306,092,819Oct 05 04:40 PM
Bauerlein AlisonOfficerOct 02 '26Proposed Sale8.8525,260223,632Oct 02 04:34 PM
Taylor BrentonOfficerOct 02 '26Proposed Sale8.852,98826,453Oct 02 04:05 PM
Rodberg JamesOfficerOct 02 '26Proposed Sale8.857,20863,814Oct 02 04:00 PM
Badawi PaulOfficerOct 01 '26Proposed Sale9.0529,653268,333Oct 01 04:49 PM
Badawi DavidOfficerOct 01 '26Proposed Sale9.057,79770,556Oct 01 04:42 PM
HAYDEN JEREMY B.Former OfficerOct 01 '26Proposed Sale9.022,74624,769Oct 01 04:25 PM
HAYDEN JEREMY B.Former OfficerSep 30 '26Proposed Sale9.3522,254208,052Sep 30 04:32 PM
HAYDEN JEREMY B.Former OfficerSep 04 '26Proposed Sale8.2912,219101,266Sep 04 04:30 PM

Held by

AUM
TickerCompanyAUM
IWMiShares Russell 2000 Index FundAUM: 77.38B
VTIVanguard Morningstar Total Stock Market ETFAUM: 687.42B
VXFVanguard Extended Market Index ETFAUM: 30.47B
IWOiShares Russell 2000 Growth ETFAUM: 14.06B
SMLFiShares U.S. Small-Cap Equity Factor ETFAUM: 4.26B
SCHASchwab U.S. Small-Cap ETFAUM: 22.25B
VTWOVanguard Russell 2000 Index ETFAUM: 16.75B
DWASInvesco Dorsey Wright SmallCap Momentum ETFAUM: 391.13M
DFASU.S. Small Cap Portfolio-ETF Class SharesAUM: 15.51B
IWCiShares Micro-Cap ETFAUM: 1.22B

News

latest 14 of 200
  • Sight Sciences to Present at Two Upcoming Investor Conferences (GlobeNewswire)
  • Sight Sciences Announces CMS Establishment of a Practice Expense Supply Code for TearCare SmartLids (GlobeNewswire)
  • Sight Sciences Lands A Record Top-Line Beat And Third Straight Guidance Raise, But Misses The Whisper And Implies A Q4 Pause After A 63% Run (Earnings Whispers)
  • Sight Sciences Reports Third Quarter 2026 Financial Results and Raises Full-Year 2026 Revenue Guidance (GlobeNewswire)
  • Sight Sciences Faces A Dry Eye Test After A 56% Rally And Two Guidance Raises (Earnings Whispers)
  • Sight Sciences to Report Third Quarter 2026 Financial Results on November 4, 2026 (GlobeNewswire)
  • Sight Sciences to Debut the OMNI Ultra Surgical System, the Latest Technology Advancement from the Pioneers of Ab Interno Canaloplasty, at the 2026 American Academy of Ophthalmology (AAO) Annual Meeting (GlobeNewswire)
  • Sight Sciences to Present at the Upcoming Morgan Stanley Global Healthcare Conference on September 15 (GlobeNewswire)
  • TearCare Becomes the First and Only MGD Treatment Indicated to Improve Meibomian Gland Function in Patients with Evaporative Dry Eye Disease (GlobeNewswire)
  • Sight Sciences Inc (SGHT) (Q2 2026) Earnings Call Highlights: Record Revenue Growth and Raised ... (GuruFocus.com) +27.75%
  • Sight Sciences Reports Second Quarter 2026 Financial Results (GlobeNewswire)
  • Sight Sciences Announces Aetna Coverage for OMNI and SION Surgical Systems (GlobeNewswire)
  • Sight Sciences Receives FDA 510(k) Clearance of the OMNI Ultra Surgical System (GlobeNewswire)
  • Earnings To Watch: Sight Sciences Inc (SGHT) Q2 2026 -- GF Value Sees 9% Downside (GuruFocus.com)

Quarterly earnings

actual against estimate
PeriodReportedEPS actEPS estEPS repSales actSales estAnalysts
2026Q32026-11-04-0.120-0.123-0.12024.9223.555
2026Q22026-08-05-0.080-0.166-0.08223.3921.725
2026Q12026-05-06-0.240-0.175-0.24119.7018.466
2025Q42026-03-04-0.080-0.139-0.07820.3920.358
2025Q32025-11-06-0.160-0.253-0.15619.9117.747
2025Q22025-08-07-0.230-0.263-0.23019.5618.187
2025Q12025-05-08-0.280-0.283-0.27617.5116.518
2024Q42025-03-05-0.230-0.204-0.23319.0719.308
2024Q32024-11-07-0.220-0.208-0.22020.1620.407
2024Q22024-08-01-0.250-0.296-0.24721.3721.346
2024Q12024-05-02-0.330-0.276-0.32919.2718.406
2023Q42024-03-07-0.220-0.318-0.21918.7518.956
2023Q32023-11-07-0.270-0.318-0.26820.0121.596
2023Q22023-08-03-0.300-0.342-0.30423.4722.407
2023Q12023-05-04-0.350-0.391-0.35318.8218.877
2022Q42023-03-13-0.350-0.417-0.35120.5420.267

Annual earnings

PeriodEPS actEPS estEPS repSales actSales est
2021FY-2.360-2.436-1.32548.9648.18
2022FY-1.800-1.868-1.80271.3371.04
2023FY-1.140-1.239-1.14281.0681.17
2024FY-1.030-0.964-1.02779.8780.06
2025FY-0.740-0.734-0.74077.3677.31
2026FY--0.516--92.30
2027FY--0.452--103.31
2028FY--0.470--112.67
2029FY--0.340--120.4

Estimate revisions

last 14 periods
PeriodTypeDateEstimatesUpDownMeanLowHigh
2026Q4S2026-11-0587024.4423.8424.94
2026Q4S2026-11-0480023.7123.3024.10
2026Q4S2026-10-2080023.7123.3024.10
2026Q4S2026-10-1487023.7123.3024.10
2026Q4S2026-08-0677023.7123.3024.10
2026Q4S2026-07-2770022.7721.9023.40
2026Q4S2026-07-2160022.6621.9023.10
2026Q4S2026-06-0461222.6621.9023.10
2026Q4S2026-05-1961222.6721.9023.10
2026Q4S2026-05-0764222.6721.9023.10
2026Q4S2026-04-1365022.8821.9023.70
2026Q4S2026-03-2465022.8821.9023.70
2026Q4S2026-03-0575023.0021.9023.70
2026Q4S2026-02-2761122.6121.2023.72

Estimate history

EPS, annual-0.306-0.553-0.742-1.325-1.802-1.142-1.027-0.737-0.5241
Period20182019202020212022202320242025TTM
EPS, quarterly-0.22-0.233-0.276-0.23-0.156-0.078-0.241-0.082-0.124
PeriodQ3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Sales, annual7.5323.34827.6448.95671.33181.05679.86677.36388.39
Period20182019202020212022202320242025TTM
Sales, quarterly20.15719.07417.50819.56419.90620.38519.69823.38824.923
PeriodQ3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Shares, annual46.76646.76646.76647.50548.29849.13150.93853.49455.219
Period20182019202020212022202320242025MRQ
Shares, quarterly50.39850.93851.37752.03352.47453.49454.03454.71655.219
PeriodQ3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26

Income statement, annual

Currency USD, millions
MetricTTM2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY
Total Revenue88.3977.3679.8781.0671.3348.9627.6423.357.53
Cost of Goods Sold Incl. D&A10.8310.7011.5811.8812.368.619.316.542.34
Gross Profit77.5666.6768.2869.1758.9740.3518.3316.805.19
Selling, General and Administrative Excl. Other103.66103.77118.82126.45142.9291.8252.7240.8419.49
Research and Development10.2014.6117.9917.5622.8615.639.178.125.43
Other Operating Expense0.000.000.000.000.000.000.000.000.00
Operating Income-26.10-37.10-50.53-57.27-83.95-51.48-34.39-24.04-14.30
Interest Expense5.165.144.665.414.474.372.401.96-
Unusual Expense0.000.001.960.000.006.86-2.140.040.00
Net Income Before Taxes-28.34-38.42-51.27-55.44-86.19-62.77-34.63-25.86-14.30
Income Taxes0.060.010.240.110.050.190.060.01-0.01
Consolidated Net Income-28.40-38.43-51.51-55.55-86.24-62.96-34.69-25.87-14.29
Net Income From Continuing Operations-28.40-38.43-51.51-55.55-86.24-62.96-34.69-25.87-14.29
Net Income-28.40-38.43-51.51-55.55-86.24-62.96-34.69-25.87-14.29
EPS (Recurring)-0.52-0.74-1.00-1.14-1.80-1.22-0.77-0.55-0.31
EPS (Basic, Before Extraordinaries)-0.52-0.74-1.03-1.14-1.80-1.33-0.74-0.55-0.31
EPS (Diluted)-0.52-0.74-1.03-1.14-1.80-1.33-0.74-0.55-0.31
EBITDA-25.68-36.61-49.82-56.66-82.70-50.28-33.27-23.61-14.23
Non-Operating Income (Expense)2.923.835.887.252.23-0.070.020.170.00
Other After Tax Adjustments0.000.000.000.000.000.000.000.000.00
Stock Option Compensation Expense8.9310.3113.4911.5210.243.710.360.090.04
Price To Sales Ratio5.845.352.283.108.1917.05---
Gross Margin87.7486.1785.5085.3482.6782.4166.3271.9768.95
Operating Margin-29.52-47.95-63.27-70.66-117.70-105.15-124.41-102.96-189.87
Net Margin-32.13-49.67-64.49-68.53-120.90-128.61-125.52-110.80-189.77
Shares Outstanding55.2253.4950.9449.1348.3047.5046.7746.7746.77
Market Capitalization597.47597.47184.75251.55587.93831.19836.87--

Income statement, quarterly

Currency USD, millions
Metric2026Q32026Q22026Q12025Q42025Q32025Q22025Q12024Q4
Total Revenue24.9223.3919.7020.3919.9119.5617.5119.07
Cost of Goods Sold Incl. D&A3.502.012.722.602.712.982.412.51
Gross Profit21.4221.3716.9817.7917.2016.5915.0916.56
Selling, General and Administrative Excl. Other27.5525.2629.3921.4625.1028.2528.9528.49
Research and Development2.712.512.552.443.354.394.434.29
Other Operating Expense0.000.000.000.000.000.000.000.00
Operating Income-6.13-3.89-12.41-3.67-7.91-11.67-13.86-11.93
Interest Expense1.311.291.271.291.311.281.261.16
Unusual Expense0.000.000.000.000.000.000.000.00
Net Income Before Taxes-6.80-4.42-12.97-4.15-8.25-11.90-14.11-11.81
Income Taxes0.010.030.010.01-0.080.040.040.04
Consolidated Net Income-6.81-4.45-12.98-4.16-8.17-11.94-14.15-11.85
Net Income From Continuing Operations-6.81-4.45-12.98-4.16-8.17-11.94-14.15-11.85
Net Income-6.81-4.45-12.98-4.16-8.17-11.94-14.15-11.85
EPS (Recurring)-0.12-0.08-0.24-0.08-0.16-0.23-0.28-0.23
EPS (Basic, Before Extraordinaries)-0.12-0.08-0.24-0.08-0.16-0.23-0.28-0.23
EPS (Diluted)-0.12-0.08-0.24-0.08-0.16-0.23-0.28-0.23
EBITDA-6.02-3.79-12.31-3.56-7.80-11.54-13.71-11.75
Non-Operating Income (Expense)0.640.760.710.800.961.051.011.28
Other After Tax Adjustments0.000.000.000.000.000.000.000.00
Stock Option Compensation Expense2.322.342.252.011.913.033.353.09
Price To Sales Ratio5.843.542.565.442.372.801.582.32
Gross Margin85.9491.3986.1987.2686.3984.7886.2186.82
Operating Margin-24.59-16.62-63.02-18.00-39.71-59.64-79.16-62.54
Net Margin-27.32-19.01-65.90-20.42-41.04-61.04-80.84-62.11
Shares Outstanding55.2254.7254.0353.4952.4752.0351.3850.94
Market Capitalization597.47294.90203.60419.27180.14213.53123.20184.75

Balance sheet, annual

Currency USD, millions
Metric2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY
Cash & Short Term Investments91.97120.36138.13185.00260.6961.5121.244.24
Short Term Receivables9.7410.7914.2915.158.715.364.091.81
Inventories7.776.337.856.113.482.602.240.49
Other Current Assets3.262.312.603.424.161.160.430.62
Total Current Assets112.73139.77162.87209.68277.0470.6328.007.16
Net Property, Plant & Equipment2.052.523.103.192.951.792.570.87
Total Investments and Advances0.000.000.000.000.000.000.000.00
Intangible Assets---0.000.000.00--
Other Assets0.520.550.680.210.200.390.170.06
Total Assets115.30142.84166.65213.07280.1972.8130.748.09
Short Term Debt Incl. Current Port. of LT Debt0.470.532.791.030.510.400.560.00
Accounts Payable1.341.691.732.693.352.162.311.88
Other Current Liabilities9.2113.247.7314.109.646.764.461.02
Total Current Liabilities11.0315.4712.2517.8213.509.317.342.90
Long Term Debt40.3039.8332.6233.9533.70149.4277.6434.15
Provision for Risks Charges0.000.000.000.000.000.000.000.00
Other Liabilities0.030.021.561.230.882.920.450.01
Total Liabilities51.3655.3246.4453.0048.08161.6685.4237.06
Non-Equity Reserves0.000.000.000.000.000.000.000.00
Preferred Stock - Carrying Value0.000.000.000.000.000.000.000.00
Common Equity63.9487.52120.22160.08232.11-88.85-54.68-28.96
Total Shareholders Equity63.9487.52120.22160.08232.11-88.85-54.68-28.96
Accumulated Minority Interest0.000.000.000.000.000.000.000.00
Total Equity63.9487.52120.22160.08232.11-88.85-54.68-28.96
Total Liabilities & Stockholders Equity115.30142.84166.65213.07280.1972.8130.748.09
Book Value Per Share1.201.722.453.314.89-1.90-1.17-0.62
Tangible Book Value Per Share1.201.722.453.314.89-1.90-1.17-0.62
Full-Time Employees186216214250212136--
Price to Book Ratio12.081.931.963.393.603.40--
Return on Assets-29.77-33.29-29.26-34.97-35.67-67.01-133.23-
Return on Equity-50.74-49.59-39.64-43.98-87.90---
Return on Invested Capital-36.86-40.44-36.34-44.45-23.69-57.28-112.69-275.28
Quick Ratio9.528.6312.6511.4320.267.303.512.31
Current Ratio10.229.0413.2911.7720.527.583.822.47

Cash flow, annual

Currency USD, millions
MetricTTM2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY
Net Income-28.40-38.43-51.51-55.55-86.24-62.96-34.69-25.87-14.29
Depreciation0.410.490.710.611.251.201.120.430.06
Other Funds (Non Cash)12.7914.6419.4416.8814.7213.540.620.780.11
Funds from Operations-15.19-23.30-31.35-38.05-70.27-48.22-32.96-24.66-14.12
Extraordinary Item0.000.000.000.000.000.000.000.000.00
Changes in Working Capital-1.73-6.399.00-9.13-5.70-4.330.78-0.34-0.36
Cash from Operating Activities-16.92-29.69-22.35-47.18-75.97-52.54-32.17-25.00-14.47
Capital Expenditures0.01-0.22-0.39-0.79-0.97-0.81-0.95-0.67-0.57
Net Assets From Acquisitions0.000.000.000.000.000.000.000.000.00
Sale of Fixed Assets and Businesses0.000.000.000.000.000.000.000.000.00
Purchase or Sale of Investments0.000.000.000.000.000.000.000.000.00
Purchase of Investments0.000.000.000.000.000.000.000.000.00
Sale Or Maturity of Investments0.000.000.000.000.000.000.000.000.00
Other Uses0.000.000.000.000.000.000.000.000.00
Other Sources0.000.000.000.000.000.000.000.000.00
Cash from Investing Activities0.01-0.22-0.39-0.79-0.97-0.81-0.95-0.67-0.57
Cash Dividends Paid0.000.000.000.000.000.000.000.000.00
Change in Capital Stock1.971.851.071.331.25252.5353.1030.1312.20
Repurchase of Common Pref Stock0.000.000.000.000.000.000.000.000.00
Sale of Common Pref Stock1.971.851.071.331.25252.5353.1030.1312.20
Proceedsfrom Stock Options0.800.760.820.930.00252.1753.4030.7512.23
Issuance or Reduction of Debt, Net0.000.003.910.000.000.0020.3412.530.00
Change in Long Term Debt0.000.003.910.000.000.0020.3412.530.00
Issuance of Long Term Debt0.000.0039.290.000.000.0020.3412.530.00
Reduction of Long Term Debt0.000.00-35.380.000.000.000.000.000.00
Net Financing Active Other Cash Flow-0.02-0.06-0.02-0.220.000.00-0.040.000.00
Other Financing Activities Uses-0.02-0.06-0.02-0.220.000.00-0.040.000.00
Cash from Financing Activities1.951.794.961.101.25252.5373.4042.6612.20
Net Change in Cash-14.97-28.13-17.77-46.87-75.69199.1840.2717.00-2.84
Free Cash Flow-16.91-29.92-22.74-47.98-76.94-53.35-33.13-25.67-15.04
Preferred Dividends (Cash Flow)-0.000.000.000.000.000.000.000.00
Deferred Taxes & Investment Tax Credit-0.000.000.000.000.000.000.000.00

Balance sheet, quarterly

Currency USD, millions
Metric2026Q32026Q22026Q12025Q42025Q32025Q2
Cash & Short Term Investments77.4079.7584.9691.9792.37101.50
Short Term Receivables13.3811.3910.609.749.749.61
Inventories6.505.707.017.777.986.21
Other Current Assets4.194.613.953.263.492.10
Total Current Assets101.47101.44106.51112.73113.59119.43
Net Property, Plant & Equipment2.792.852.822.052.112.15
Total Investments and Advances0.000.000.000.000.000.00
Other Assets0.690.580.370.520.550.39
Total Assets104.95104.87109.70115.30116.26121.97
Short Term Debt Incl. Current Port. of LT Debt6.4610.534.160.470.570.57
Accounts Payable2.781.901.491.341.742.08
Other Current Liabilities10.898.0812.529.219.529.29
Total Current Liabilities20.1420.5018.1611.0311.8311.94
Long Term Debt35.6431.4536.7440.3040.1240.00
Provision for Risks Charges0.000.000.000.000.000.00
Other Liabilities0.030.030.900.030.020.02
Total Liabilities55.8151.9855.8051.3651.9751.96
Non-Equity Reserves0.000.000.000.000.000.00
Preferred Stock - Carrying Value0.000.000.000.000.000.00
Common Equity49.1452.8953.9063.9464.2970.01
Total Shareholders Equity49.1452.8953.9063.9464.2970.01
Accumulated Minority Interest0.000.000.000.000.000.00
Total Equity49.1452.8953.9063.9464.2970.01
Total Liabilities & Stockholders Equity104.95104.87109.70115.30116.26121.97
Book Value Per Share0.890.971.001.201.231.35
Tangible Book Value Per Share0.890.971.001.201.231.35
Full-Time Employees---186--
Price to Book Ratio12.085.433.156.472.562.73
Return on Assets-25.68-26.24-31.12-29.77-35.49-36.08
Return on Equity-50.07-48.42-56.64-50.74-57.91-57.10
Return on Invested Capital-8.03-5.27-14.32-3.99-7.82-10.85
Quick Ratio4.724.675.489.528.939.49
Current Ratio5.044.955.8610.229.6010.01

Cash flow, quarterly

Currency USD, millions
Metric2026Q32026Q22026Q12025Q42025Q32025Q2
Net Income-6.81-4.45-12.98-4.16-8.17-11.94
Depreciation0.110.090.100.110.100.12
Other Funds (Non Cash)3.383.353.053.022.794.22
Funds from Operations-3.33-1.01-9.83-1.03-5.28-7.59
Extraordinary Item0.000.000.000.000.000.00
Changes in Working Capital0.92-4.662.80-0.80-3.440.05
Cash from Operating Activities-2.40-5.66-7.03-1.83-8.72-7.54
Capital Expenditures-0.07-0.02-0.060.16-0.17-0.21
Net Assets From Acquisitions0.000.000.000.000.000.00
Sale of Fixed Assets and Businesses0.000.000.000.000.000.00
Purchase or Sale of Investments0.000.000.000.000.000.00
Purchase of Investments0.000.000.000.000.000.00
Sale Or Maturity of Investments0.000.000.000.000.000.00
Other Uses0.000.000.000.000.000.00
Other Sources0.000.000.000.000.000.00
Cash from Investing Activities-0.07-0.02-0.060.16-0.17-0.21
Cash Dividends Paid0.000.000.000.000.000.00
Preferred Dividends (Cash Flow)0.000.000.000.000.000.00
Change in Capital Stock0.120.480.101.270.030.49
Repurchase of Common Pref Stock0.000.000.000.000.000.00
Sale of Common Pref Stock0.120.480.101.270.030.49
Proceedsfrom Stock Options0.000.480.000.33-0.000.43
Issuance or Reduction of Debt, Net0.000.000.000.000.000.00
Change in Long Term Debt0.000.000.000.000.000.00
Issuance of Long Term Debt0.000.000.000.000.000.00
Reduction of Long Term Debt0.000.000.000.000.000.00
Net Financing Active Other Cash Flow-0.00-0.00-0.01-0.00-0.00-0.01
Other Financing Activities Uses-0.00-0.00-0.01-0.00-0.00-0.01
Cash from Financing Activities0.120.470.091.260.030.48
Net Change in Cash-2.35-5.21-7.00-0.41-8.86-7.27
Free Cash Flow-2.47-5.68-7.09-1.67-8.89-7.75

Revenue breakdown

United States2024: 79.87M 2025: 77.36M
Dry Eye2024: 3.96M 2025: 1.64M
Surgical Glaucoma2024: 75.90M 2025: 75.72M

Short interest

shares short against float, oldest to newest
SettlementOf floatShares shortFloatAvg volume
2026-10-303.14%1.1M36.2M291.27K
2026-10-153.46%1.2M35.9M272.54K
2026-09-303.98%1.4M35.6M241.41K
2026-09-153.52%1.3M35.6M225.79K
2026-08-313.44%1.2M35.6M220.83K
2026-08-142.48%0.9M35.6M211.42K
2026-07-312.33%0.8M35.4M184.80K
2026-07-152.37%0.8M35.0M239.13K
2026-06-302.08%0.7M35.0M247.91K
2026-06-152.24%0.8M36.0M256.67K
2026-05-292.48%0.9M36.0M330.65K
2026-05-152.39%0.9M36.0M340.79K
2026-04-302.89%0.9M32.4M337.56K
2026-04-153.37%1.1M31.9M306.26K
2026-03-313.67%1.1M29.1M322.98K
2026-03-133.77%1.1M29.1M333.76K
2026-02-273.42%1.0M29.1M261.72K
2026-02-133.74%1.1M28.5M261.04K
2026-01-303.84%1.1M28.3M271.82K
2026-01-154.10%1.2M28.3M278.98K

Option chain

expiry 2026-11-20
TypeStrikeBidAskLastIVOpen intVolumeDeltaThetaVega
call2.507.409.402.5012.3231.000.000.988-0.0160.001
call5.005.107.303.518.13651.000.000.977-0.0160.001
call7.502.604.402.204.12458.000.000.957-0.0140.002
call10.000.251.950.972.22846.000.000.676-0.0640.006
call12.500.003.300.253.4985.000.000.510-0.1350.007
call15.000.001.950.104.1254.000.000.432-0.1560.007
put2.500.003.800.055.13912.000.00-0.012-0.0160.001
put5.000.000.750.202.8485.000.00-0.023-0.0150.001
put7.500.003.800.351.5182.000.00-0.043-0.0130.002
put10.000.000.750.201.7885.000.00-0.324-0.0620.006
put12.501.102.700.002.5100.000.00-0.477-0.1410.007
put15.003.605.600.004.0290.000.00-0.530-0.1760.007

Latest SEC filings

30
FiledFormDescriptionPeriodLink
2026-11-05144Filing for proposed sale of securities under Rule 144.SEC
2026-11-0410-QQuarterly report pursuant to Section 13 or 15(d)2026-09-30SEC
2026-11-048-KCurrent report2026-11-04SEC
2026-10-054Statement of changes in beneficial ownership of securities2026-10-02SEC
2026-10-054Statement of changes in beneficial ownership of securities2026-10-02SEC
2026-10-054Statement of changes in beneficial ownership of securities2026-10-02SEC
2026-10-054Statement of changes in beneficial ownership of securities2026-10-01SEC
2026-10-054Statement of changes in beneficial ownership of securities2026-10-01SEC
2026-10-02144Filing for proposed sale of securities under Rule 144.SEC
2026-10-02144Filing for proposed sale of securities under Rule 144.SEC
2026-10-02144Filing for proposed sale of securities under Rule 144.SEC
2026-10-01144Filing for proposed sale of securities under Rule 144.SEC
2026-10-01144Filing for proposed sale of securities under Rule 144.SEC
2026-10-01144Filing for proposed sale of securities under Rule 144.SEC
2026-09-30144Filing for proposed sale of securities under Rule 144.SEC
2026-09-04144Filing for proposed sale of securities under Rule 144.SEC
2026-09-01144Filing for proposed sale of securities under Rule 144.SEC
2026-08-184Statement of changes in beneficial ownership of securities2026-08-10SEC
2026-08-183Initial statement of beneficial ownership of securities2026-08-10SEC
2026-08-17144Filing for proposed sale of securities under Rule 144.SEC
2026-08-14144Filing for proposed sale of securities under Rule 144.SEC
2026-08-13144Filing for proposed sale of securities under Rule 144.SEC
2026-08-12144Filing for proposed sale of securities under Rule 144.SEC
2026-08-11144Filing for proposed sale of securities under Rule 144.SEC
2026-08-108-KCurrent report2026-08-06SEC
2026-08-0510-QQuarterly report pursuant to Section 13 or 15(d)2026-06-30SEC
2026-08-058-KCurrent report2026-08-05SEC
2026-07-06144Filing for proposed sale of securities under Rule 144.SEC
2026-07-06144Filing for proposed sale of securities under Rule 144.SEC
2026-07-064Statement of changes in beneficial ownership of securities2026-07-06SEC

Insider activity by month

MonthBoughtBuysSoldSells
2026-110000
2026-1000652.78K5
2026-090000
2026-080000
2026-0700448.41K6
2026-0668.79K100
2026-050065.17K1
2026-0400311.81K6
2026-030000
2026-020000
2026-0100877.09K16
2025-12115.96K120.77K1
2025-1100489.41K3

Institutional holders

Manager% owned
Long Focus Capital Management, LLC7.07%
BlackRock, Inc.5.67%
Americana Partners, LLC3.09%
Pathstone Holdings, LLC3.09%
VANGUARD CAPITAL MANAGEMENT LLC2.89%
B Group, Inc.1.78%
GEODE CAPITAL MANAGEMENT, LLC1.78%
STATE STREET CORP1.54%
ACADIAN ASSET MANAGEMENT LLC1.53%
AQR CAPITAL MANAGEMENT LLC0.73%

Funds

Fund% owned
VANGUARD TOTAL STOCK MARKET INDEX FUND2.10%
iShares Russell 2000 ETF1.89%
Fidelity Small Cap Index Fund0.79%
VANGUARD EXTENDED MARKET INDEX FUND0.70%
iShares Russell 2000 Growth ETF0.69%
iShares U.S. Small-Cap Equity Factor ETF0.50%
VANGUARD RUSSELL 2000 INDEX FUND0.41%
Fidelity Extended Market Index Fund0.31%
Schwab U.S. Small-Cap ETF0.29%
iShares Micro-Cap ETF0.24%

OakChart. SGHT. Cached 15 minutes.